Yes, I believe the same. While not quite answered completely, in a conversation I had with Les years ago, I got the impression that the revenue from compassionate care was netted-out in the R&D bucket. I don't know why it is better to do that, other than to keep things murky for competitive purposes. Of course we know the FUDsters here will say it's so Linda can build out Advent on our dime.
Yes there are a lot of hands on steps and processes from beginning to vaccine production and then distribution.
FlaskWorks will help greatly with some of these, and efficiencies of scale will likely also improve costs.
Again we should remember oncology is a very profitable business for the status quo, and even DCVax prices will compare favorably, especially if it works well for particular patients and more broadly in combination treatments to follow.
News 
Market Data 
Discover 
